[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350225-105":59,"doc-detail-350225-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","c-type-lectin-domain-family-5-member-a-mediated-activation-of-macrophages-via-a-bispecific-antibody-enhances-anti-her2-therapy","C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy","","HER2-targeted therapies improve outcomes in HER2-positive breast cancer, yet the immunosuppressive tumor microenvironment blocks effective immunotherapy. This study develops a bispecific antibody targeting HER2 and CLEC5A, a pattern-recognition receptor on innate immune cells, to reshape the tumor immune milieu. In vitro assays evaluate binding, macrophage activation, and phagocytosis, while syngeneic mouse models assess anti-tumor efficacy with mechanistic and checkpoint-combination studies.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/c-type-lectin-domain-family-5-member-a-mediated-activation-of-macrophages-via-a-bispecific-antibody-enhances-anti-her2-therapy/350225/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/c-type-lectin-domain-family-5-member-a-mediated-activation-of-macrophages-via-a-bispecific-antibody-enhances-anti-her2-therapy/350225.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why target HER2 and CLEC5A simultaneously in HER2-positive breast cancer?","Question",{"text":112,"@type":113},"The study targets HER2 while engaging CLEC5A on macrophages to counteract an immunosuppressive, T cell–poor tumor microenvironment. This aims to remodel the tumor immune environment to support effective immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the bispecific antibody evaluated in this research?",{"text":117,"@type":113},"The antibody was generated and tested for binding properties, macrophage activation, and phagocytic activity in vitro. Anti-tumor efficacy was then assessed in multiple syngeneic mouse models, including orthotopic breast cancer models.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune changes did the CLEC5A-HER2 bispecific antibody induce?",{"text":121,"@type":113},"Mechanistically, it promoted macrophage-mediated phagocytosis and shifted tumor-associated macrophages toward an M1-like phenotype. It also enhanced antigen presentation and T-cell recruitment, restoring the CXCL9/10-CXCR3 axis and increasing CD8+ T cell infiltration while reducing regulatory T cells.",{"name":123,"@type":110,"acceptedAnswer":124},"Do checkpoint inhibitor combinations enhance the therapy?",{"text":125,"@type":113},"Yes. Combination therapy with CTLA-4 and PD-1 blockade showed strong synergistic effects without significant toxicity, supporting potential clinical translation as monotherapy or in combination.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},350225,1790154845,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Open access Original research  \n C-type lectin domain family 5 member  \nA-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy  \nLei Hou,1,2 Dechuang Jiao,1 Hao Dai,1 Jingyang Zhang,1 Lina Wang,1 Xilong Gong,1 Cuihua Qi,1 Xuhui Guo,1 ZhenZhen Liu  1  \nTo cite: Hou L, Jiao D, Dai H, et al. C-type lectin domain family 5 member A-mediated activation of macrophages via abispecific antibody enhances anti-HER2 therapy. Journal for ImmunoTherapy of Cancer 2026;14:e014799 . doi:10 . 1136/ jitc-2026-014799  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2026-014799](jitc-2026-014799)) .  \nLH, DJ, HD and JZ are joint first authors.  \nAccepted 09 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Department of Breast Disease, Henan Breast Cancer Centre, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan, China  \n2Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China  \nCorrespondence to  \nDr ZhenZhen Liu;  \nzlyyliuzhenzhen0800@zzu. [edu.cn](edu.cn)  \nABSTRACT  \nBackground Although HER2-targeted therapies have dramatically improved outcomes for patients with HER2-positive breast cancer, the immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in this subtype. Therefore, we sought to develop a new bispecific antibody targeting both HER2 and C-type lectin domain family 5 member A (CLEC5A), a pattern recognition receptor on innate immune cells like macrophages, aiming to alter the tumor immune environment.  \nMethods CLEC5A-HER2 bispecific antibodies were generated and evaluated for binding properties, macrophage activation, and phagocytic activity in vitro. Anti-tumor efficacy was assessed in multiple syngeneic mouse models, including orthotopic breast cancer models, with mechanistic studies and immune checkpoint inhibitor combinations.  \nResults The CLEC5A-HER2 bispecific antibody was more effective in anti-tumor activity than either monotherapies or combinations of individual antibodies in various syngeneic models, including an orthotopic breast cancer model. Mechanistically, it converted “cold” tumors into“hot” tumors by promoting macrophage-mediated phagocytosis, repolarizing tumor-associated macrophages toward an M1-like phenotype, and enhancing antigen presentation and T-cell recruitment. This immune remodeling restored the CXCL9/10-CXCR3 axis, increased CD8+ T cell infiltration, reduced regulatory T cells, and underpinned a T cell-dependent anti-tumor response. Interestingly, combination therapy with CTLA-4 and PD- 1 blockade exhibited strong synergistic effects without significant toxicity.  \nConclusions These results identify the CLEC5A-HER2 bispecific antibody as a potential immunotherapy for HER2-positive cancers by effectively engaging both innate and adaptive immunity.  \nINTRODUCTION  \nBreast cancer is the most prevalent malignancy in women globally, and HER2-positive breast cancer is a clinically relevant subtype due to its aggressive behavior and poor prognosis.1 2 HER2-targeted therapies, which include monoclonal antibodies such as  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ HER2-positive breast cancers often have an immunosuppressive, T cell-poor tumor microenvironment, which limits the efficacy of immune checkpoint blockade. Tumor-associated macrophages are key regulators of this suppressive state, but effective strategies to reprogram them in HER2-positive tumors are still lacking.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ We developed a CLEC5A-HER2 bispecific antibody that outperformed monotherapies and antibody combinations in multiple tumor models. It reprogrammed macrophages toward an M1-like state, restored the CXCL9/10-CX","cbCaiavvsCckObsu","https://ap.wps.com/l/cbCaiavvsCckObsu","pdf",12072392,17,"English","# Abstract\n# Introduction\n# Results and Conclusions","[{\"question\":\"Why target HER2 and CLEC5A simultaneously in HER2-positive breast cancer?\",\"answer\":\"The study targets HER2 while engaging CLEC5A on macrophages to counteract an immunosuppressive, T cell–poor tumor microenvironment. This aims to remodel the tumor immune environment to support effective immunotherapy.\"},{\"question\":\"How was the bispecific antibody evaluated in this research?\",\"answer\":\"The antibody was generated and tested for binding properties, macrophage activation, and phagocytic activity in vitro. Anti-tumor efficacy was then assessed in multiple syngeneic mouse models, including orthotopic breast cancer models.\"},{\"question\":\"What immune changes did the CLEC5A-HER2 bispecific antibody induce?\",\"answer\":\"Mechanistically, it promoted macrophage-mediated phagocytosis and shifted tumor-associated macrophages toward an M1-like phenotype. It also enhanced antigen presentation and T-cell recruitment, restoring the CXCL9/10-CXCR3 axis and increasing CD8+ T cell infiltration while reducing regulatory T cells.\"},{\"question\":\"Do checkpoint inhibitor combinations enhance the therapy?\",\"answer\":\"Yes. Combination therapy with CTLA-4 and PD-1 blockade showed strong synergistic effects without significant toxicity, supporting potential clinical translation as monotherapy or in combination.\"}]","C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy | PDF",1790087916,43,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05267abddf885f6a529b27239fb3586f.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4554ba4765549f3858bca5ceb3ad4ad.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1c89916544b5ce2a809d3d1895d5641.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cce2b764df5075f2b4627517e34c3d72.webp",980,1306]